国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > Gilead
  • Global Biopharma Layoffs January 2026
    Global Biopharma Layoffs January 2026 Layoffs This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
  • Gilead Q2 2025 Financial Report
    Gilead Q2 2025 Financial Report Financial statements Gilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.
  • Sanofi and Gilead Expand Protein Degrader Portfolios
    Sanofi and Gilead Expand Protein Degrader Portfolios Sanofi Sanofi and Gilead deepen their partnerships with Kymera Therapeutics, focusing on next-gen protein degraders for cancer and immune diseases in multi-million dollar deals, signaling rising industry interest.
  • Global Biopharma Layoffs June 2025
    Global Biopharma Layoffs June 2025 Layoffs Biopharma layoffs surge in June 2025 as major companies like Genentech, Vertex, and Recursion downsize. Explore the latest job cuts, site closures, and restructuring trends across the industry.
  • FDA Puts Gilead’s HIV Combo Trials on Hold
    FDA Puts Gilead’s HIV Combo Trials on Hold Gilead The FDA has paused five Gilead HIV combo trials over safety concerns, but the decision does not impact lenacapavir's upcoming PrEP approval. Gilead remains confident in its HIV pipeline and future plans.
  • Trodelvy Shows Strong Solo Efficacy in TNBC
    Trodelvy Shows Strong Solo Efficacy in TNBC Gilead Gilead’s Trodelvy shows significant solo efficacy in the ASCENT-03 trial, outperforming chemotherapy in previously untreated TNBC patients not eligible for immunotherapy.
  • Gilead's Q1 2025 Financial report
    Gilead's Q1 2025 Financial report Financial statements Gilead's Q1 2025 report shows stable revenue, strong HIV and hepatitis sales growth, major R&D progress, and reaffirmed full-year guidance, driven by products like Biktarvy, Trodelvy, and lenacapavir.
  • Global Biopharma Layoffs April 2025
    Global Biopharma Layoffs April 2025 Layoffs Stay updated on recent global biopharma layoffs in April 2025. Learn about job cuts, restructuring plans, and the latest industry developments across leading biotech and pharma companies.
  • 2024 Global CAR-T Sales Performance
    2024 Global CAR-T Sales Performance CAR-T Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
  • Biotech Giants Performance Comparison 2024
    Biotech Giants Performance Comparison 2024 Market Trend Compare the 2024 financial performance of top biotech giants, including Vertex, Amgen, Gilead, Regeneron, and Biogen. Explore revenue, net profit, R&D investment, and market trends shaping the biotech industry.
<Pre12Next >
萨嘎县| 江北区| 襄樊市| 临沂市| 正蓝旗| 福贡县| 金坛市| 富平县| 泰兴市| 台北市| 景德镇市| 友谊县| 中山市| 新巴尔虎左旗| 定南县| 尼玛县| 望江县| 崇左市| 澎湖县| 连云港市| 安顺市| 宜兰市| 鸡东县| 常德市| 长武县| 循化| 阿瓦提县| 调兵山市| 文山县| 镇坪县| 教育| 大连市| 泗阳县| 崇义县| 章丘市| 济源市| 汨罗市| 丰顺县| 钟山县| 新津县| 马尔康县|